May 28, 2019 10:20 AM EDTUpdated May 29, 04:46 AM

Mallinckrodt updates spin-off plans; FDA expands Vraylar approval for Allergan; Juvenescence spawns Souvien Therapeutics

Kathy Wong

Editor

→ UK-based biopharmaceutical company Mallinckrodt $MNK — the maker of the controversial drug Acthar — has updated its plans for its new spin-off company …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Mallinckrodt updates spin-off plans; FDA expands Vraylar approval for Allergan; Juvenescence spawns Souvien Therapeutics

Kathy Wong

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Mallinck­rodt up­dates spin-off plans; FDA ex­pands Vray­lar ap­proval for Al­ler­gan; Ju­ve­nes­cence spawns Sou­vien Ther­a­peu­tics

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Mallinckrodt updates spin-off plans; FDA expands Vraylar approval for Allergan; Juvenescence spawns Souvien Therapeutics